

SC halts Glenmark from selling copies of Merck's diabetes drugs

18 May 2015 | News | By BioSpectrum Bureau

SC halts Glenmark from selling copies of Merck's diabetes drugs



The SC has, however, allowed Glenmark to sell its existing stocks of these two drugs.

The judgment brings a great relief to Merck after two years, when in 2013 it sued its opponent for infringing its patent on the compound sitagliptin, which is present in both the drugs.